In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ampliphi Biosciences (AMEX: APHB), with a price target of $6. The company’s shares closed yesterday at $1.07.
“Valuation and risks to price target achievement. We reiterate our Buy rating and $6 price target. We anticipate some upcoming adjustment to our valuation based on the identification of a more delineated path to market for AmpliPhi’s phage cocktails.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -12.4% and a 31.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Checkpoint Therapeutics Inc.
Currently, the analyst consensus on Ampliphi Biosciences is a Moderate Buy with an average price target of $6.
Based on Ampliphi Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.05 million. In comparison, last year the company had a GAAP net loss of $6.46 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AmpliPhi Biosciences Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company was founded in March 1989 and is headquartered in San Diego, CA.